Belite Bio (BLTE) Change in Account Payables (2024 - 2025)

Belite Bio (BLTE) posted quarterly Change in Account Payables of -$3000.0 for Q4 2025, up 62.5% year-over-year from -$1846.2 in Q4 2024, and up 62.5% quarter-over-quarter from -$8000.0 in Q4 2024.

Belite Bio (BLTE) Change in Account Payables (2024 - 2025) Analysis & Trends

Belite Bio's Change in Account Payables history runs 2 years deep, the most recent figure standing at -$3000.0 for Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Account Payables (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -66.70 Mn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - 5.03 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 37.53 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 520,137.79
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Belite Bio 6.40 Bn 6.40 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2025 -3,000.00
Dec 31, 2025 -3,000.00
Dec 31, 2024 -8,000.00
Dec 31, 2024 -8,000.00